Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 2/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20380566 | 0.93 | AKR1C3 (0.32) | AKR1C3AKR1C2 | |
| SCHEMBL20380688 | 0.91 | FFAR4 (0.34) | ALOX5APFEN1AKR1C3AKR1C2FFAR4 | |
| SCHEMBL10021838 | 0.88 | ALOX5AP (0.38) | ALOX5APFEN1ERN1AKR1C3AKR1C2 | |
| SCHEMBL20380715 | 0.88 | ALOX5AP (0.37) | ALOX5APFEN1ERN1AKR1C3AKR1C2 | |
| SCHEMBL20380706 | 0.87 | AKR1C3 (0.32) | AKR1C3AKR1C2 | |
| SCHEMBL12357204 | 0.87 | GPR3 (0.40) | ALOX5APFEN1ERN1AKR1C3AKR1C2 | |
| SCHEMBL20380568 | 0.87 | AKR1C3 (0.31) | AKR1C3AKR1C2 | |
| SCHEMBL20380645 | 0.86 | ALOX5AP (0.39) | ALOX5APFEN1ERN1AKR1C3AKR1C2 | |
| SCHEMBL18455344 | 0.86 | ALOX5AP (0.38) | ALOX5APFEN1ERN1GRM2FFAR4 | |
| SCHEMBL18887667 | 0.86 | ALOX5AP (0.36) | ALOX5APFEN1ERN1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | PIEZO1, ROCK1, RCC1 | ALOX5AP 1442/4885FEN1 1883/4885ERN1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.